Cargando…

Are BCL6 and EZH2 novel therapeutic targets for systemic lupus erythematosus?

Detalles Bibliográficos
Autores principales:	Ding, Shu, Rao, Yu, Lu, Qianjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242986/ https://www.ncbi.nlm.nih.gov/pubmed/35637283 http://dx.doi.org/10.1038/s41423-022-00882-1

Ejemplares similares

Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study
por: Felten, Renaud, et al.
Publicado: (2021)

Systemic lupus erythematosus does not prevent antibody responses to SARS-CoV-2
por: Aringer, Martin
Publicado: (2021)

RNA Methylation in Systemic Lupus Erythematosus
por: Lv, Xinyi, et al.
Publicado: (2021)

Potential therapeutic target genes for systemic lupus erythematosus: a bioinformatics analysis
por: Yu, Yun, et al.
Publicado: (2021)

AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1–Bcl-6 axis-mediated B-cell differentiation
por: Yang, Ming, et al.
Publicado: (2021)

The Real Culprit in Systemic Lupus Erythematosus: Abnormal Epigenetic Regulation
por: Wu, Haijing, et al.
Publicado: (2015)

Extracellular Vesicles in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Functions and Applications
por: Zhang, Bo, et al.
Publicado: (2021)

Immunopathogenesis and Novel Therapeutics Strategies of Systemic Lupus Erythematosus
por: Kotyla, Przemysław, et al.
Publicado: (2023)

Comedonal variant of chronic cutaneous lupus erythematosus causing mutilation of the earlobe
por: Cozzani, Emanuele, et al.
Publicado: (2020)

Dysregulation of Cell Death and Its Epigenetic Mechanisms in Systemic Lupus Erythematosus
por: Wu, Haijing, et al.
Publicado: (2016)

Comment on the article by Opeyemi Folorunsho Bamidele, Richard Oluyinka Akintayo, Mathew Olumuyiwa Bojuwoye, et al. “Thrombotic thrombocytopenic purpura as the first presentation in systemic lupus erythematosus”
por: Maślińska, Maria
Publicado: (2018)

Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus
por: Gottschalk, Timothy A., et al.
Publicado: (2015)

Novel therapeutic agents in clinical development for systemic lupus erythematosus
por: Jordan, Natasha, et al.
Publicado: (2013)

Endoplasmic Reticulum Stress in Systemic Lupus Erythematosus and Lupus Nephritis: Potential Therapeutic Target
por: Li, Hui-Yuan, et al.
Publicado: (2023)

Long COVID: systemic inflammation and obesity as therapeutic targets
por: Florencio, Lidiane L, et al.
Publicado: (2022)

Editorial Comment to Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
por: Hatakeyama, Shingo, et al.
Publicado: (2020)

Therapeutic inhibition of proteasomes in systemic lupus erythematosus
por: Hiepe, Falk, et al.
Publicado: (2011)

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
por: Tian, Jingru, et al.
Publicado: (2023)

Drosophila Apoptosis and Bcl-2 Genes: Outliers Fly in
por: Chen, Po, et al.
Publicado: (2000)

Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside
por: Squatrito, D., et al.
Publicado: (2014)

The Potential of Nrf2 Activation as a Therapeutic Target in Systemic Lupus Erythematosus
por: Barati, Michelle T., et al.
Publicado: (2022)

GDF-15: A Potential Biomarker and Therapeutic Target in Systemic Lupus Erythematosus
por: Xu, Wang-Dong, et al.
Publicado: (2022)

EZH2: novel therapeutic target for human cancer
por: Li, Long-Yuan
Publicado: (2014)

The Systemic Lupus Erythematosus Interventional Trials in Mainland China: A Continuous Challenge
por: Tian, Jingru, et al.
Publicado: (2022)

Extracellular Vesicles as Therapeutic Agents in Systemic Lupus Erythematosus
por: Perez-Hernandez, Javier, et al.
Publicado: (2017)

To target or not to target APRIL in systemic lupus erythematosus: that is the question!
por: Morel, Jacques, et al.
Publicado: (2013)

Development of targeted biologics for systemic lupus erythematosus
por: Lipsky, Peter E
Publicado: (2012)

Interferon targeted therapies in systemic lupus erythematosus
por: Misra, Durga Prasanna, et al.
Publicado: (2017)

BclX(L) (Bcl2l1) gene therapy lessens retinal ganglion cell soma loss but not axonal degeneration after acute axonal injury
por: Marola, Olivia J., et al.
Publicado: (2022)

Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis
por: Teixeira, Vítor, et al.
Publicado: (2018)

Gas6/TAM Receptors in Systemic Lupus Erythematosus
por: Cohen, Philip L., et al.
Publicado: (2019)

Systemic lupus erythematosus.
por: Richardson, J.
Publicado: (1969)

Systemic Lupus Erythematosus
por: Peng, Stanford
Publicado: (1993)

Systemic lupus erythematosus
por: Manson, Jessica J, et al.
Publicado: (2006)

Systemic Lupus Erythematosus
por: Putterman, Chaim, et al.
Publicado: (2012)

Systemic Lupus Erythematosus
por: Okamoto, Hiroshi, et al.
Publicado: (2012)

NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
por: Brightbill, Hans D., et al.
Publicado: (2018)

3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023)

Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept
por: Tarazi, Meera, et al.
Publicado: (2018)

Hypomethylation of IL10 and IL13 Promoters in CD4(+) T Cells of Patients with Systemic Lupus Erythematosus
por: Zhao, Ming, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_l8b9v5r8foqggrd6ksokmlmng2